Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

1. WO2003000865 - PROTEINES HUMAINES SECRETEES

Numéro de publication WO/2003/000865
Date de publication 03.01.2003
N° de la demande internationale PCT/US2002/009105
Date du dépôt international 26.03.2002
Demande présentée en vertu du Chapitre 2 25.10.2002
CIB
A61K 38/00 2006.01
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
38Préparations médicinales contenant des peptides
C07K 14/47 2006.01
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
KPEPTIDES
14Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
435provenant d'animaux; provenant d'humains
46provenant de vertébrés
47provenant de mammifères
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
A61P 11/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
06Antiasthmatics
C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
Y02A 50/393
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
50in human health protection
30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
38Medical treatment of vector-borne diseases characterised by the agent
381the vector-borne disease being caused by a virus
384of the genus Flavivirus
393the disease being West Nile fever
Y02A 50/395
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
50in human health protection
30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
38Medical treatment of vector-borne diseases characterised by the agent
381the vector-borne disease being caused by a virus
384of the genus Flavivirus
395the disease being Tick-borne encephalitis [TBE]
Déposants
  • HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue Rockville, MD 20850, US (AllExceptUS)
  • ROSEN, Craig, A. [US/US]; US (UsOnly)
  • RUBEN, Steven, M. [US/US]; US (UsOnly)
Inventeurs
  • ROSEN, Craig, A.; US
  • RUBEN, Steven, M.; US
Mandataires
  • HOOVER, Kenley, K.; Human Genome Sciences, Inc. 9410 Key West Avenue Rockville, MD 20850, US
  • MARTINEAU, Janet, M.; Human Genome Sciences, Inc. 9410 Key West Avenue Rockville, MD 20850, US
Données relatives à la priorité
09/950,08212.09.2001US
09/950,08312.09.2001US
60/278,65027.03.2001US
Langue de publication anglais (EN)
Langue de dépôt anglais (EN)
États désignés
Titre
(EN) HUMAN SECRETED PROTEINS
(FR) PROTEINES HUMAINES SECRETEES
Abrégé
(EN)
The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diabetes mellitus and/or conditions related to diabetes. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.
(FR)
L'invention porte sur des polypeptides humains sécrétés, sur des molécules d'acide nucléique isolées codant pour lesdits polypeptides qui sont utiles pour diagnostiquer et traiter le diabète sucré et/ou des états liés au diabète, sur des anticorps se fixant auxdits polypeptides, sur des vecteurs, cellules hôtes et produits de recombinaison, sur des procédés de synthèse permettant d'obtenir lesdits polynucléotides, polypeptides, et/ou anticorps, sur des procédés de criblage permettant d'identifier les agonistes et antagonistes des polynucléotides et polypeptides de l'invention, et sur des méthodes et compositions inhibant ou favorisant la production et les fonctions des polypeptides de l'invention.
Également publié en tant que
RU2004103981
Dernières données bibliographiques dont dispose le Bureau international